Author

Benjamin K. Eschle

Dana-Farber Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Prafulla C. GokhaleiD· 2 shared Andrew A. LaneiD· 1 shared Brittaney A. LeeperiD· 1 shared Christopher Alexander FrenchiD· 1 shared David G. J. CucchiiD· 1 shared Dustin Rogers· 1 shared Erica A. K. DePasqualeiD· 1 shared Fadi J. NajmiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Prafulla C. GokhaleORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BET BD2 inhibition facilitates SPOP-mediated degradation of chromatin-associated BRD4/BRD4-NUT, a therapeutic vulnerability in NUT carcinoma

Kathleen Bates, Hoang Nguyen, Kyle P. Eagen, Julianna Huang, Prafulla C. Gokhale, Brittaney A. Leeper, Benjamin K. Eschle, Stacey T Gray, Krupa Sampat, Taylor R Durall, Jia Luo, Geoffrey Ira Shapiro, Steven J. Ferrara, Jacob Gillis, Dustin Rogers, , Christopher Alexander French

The paper shows that selective inhibition of BRD4-BD2 promotes SPOP-mediated degradation of BRD4/BRD4-NUT in NUT carcinoma, leading to better therapeutic outcomes than pan-BET inhibition.

bioRxiv · Aug 19, 2026 · PreprintCancer Biology

Translation Initiation Represents an Acute Myeloid Leukemia Cell Vulnerability That Can Be Co-Targeted With BCL-2 Inhibition

Yoke Seng Lee, Jonathan Good, Noha Awais, Benjamin K. Eschle, Maia S. Lineberry, Jessica L. Teo, Sarah Bibeau, Morgan Wollman, George I Karadimov, Nurefsan E. Sariipek, Jean Acosta, Jenny Noel, David G. J. Cucchi, Erica A. K. DePasquale, Prafulla C. Gokhale, , Peter van Galen

The paper identifies EIF4A1 as a vulnerability in AML cells and shows that combining Zotatifin with Venetoclax enhances apoptosis and survival in AML models.

bioRxiv · Dec 20, 2024 · PreprintCancer Biology